Hetero announces the approval from DCGI for the generic version of 'Daclatasvir'

India, Hyderabad, December 14th, 2015: Hetero, one of India's leading generic pharmaceutical companies and one of the world's largest producer of anti-retroviral drugs, today announced that it has received the approval from Drug Controller General of India (DCGI) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.

This product is a generic version of Bristol-Myers Squibb's brand 'Daklinza' - approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment. Research studies indicates that this drug enables the rapid decline of Hepatitis C virus. Daclatasvir is included the World Health Organization's List of Essential medicines.

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.